[go: up one dir, main page]

PE20190150A1 - 6-AMINOPIRIDIN-3-IL TIAZOLES COMO MODULADORES DE RORyT - Google Patents

6-AMINOPIRIDIN-3-IL TIAZOLES COMO MODULADORES DE RORyT

Info

Publication number
PE20190150A1
PE20190150A1 PE2018002176A PE2018002176A PE20190150A1 PE 20190150 A1 PE20190150 A1 PE 20190150A1 PE 2018002176 A PE2018002176 A PE 2018002176A PE 2018002176 A PE2018002176 A PE 2018002176A PE 20190150 A1 PE20190150 A1 PE 20190150A1
Authority
PE
Peru
Prior art keywords
alkyl
aminopyridin
thiazoles
compounds
chf2
Prior art date
Application number
PE2018002176A
Other languages
English (en)
Inventor
Kelly Mcclure
Virginia M Tanis
Elizabeth G Fennema
Alec D Lebsack
Connor L Martin
Hariharan Venkatesan
Xiaohua Xue
Craig R Woods
Steven Goldberg
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of PE20190150A1 publication Critical patent/PE20190150A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Image Processing (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

SE REFIERE A COMPUESTOS DERIVADOS DE 6-AMINOPIRIDIN-3-IL-TIAZOLES DE FORMULA (I) DONDE A1 Y A2 JUNTO AL NITROGENO AL QUE ESTAN UNIDOS FORMAN ANILLOS DE FORMULA (i), (ii), ENTRE OTROS; A3 ES H, ALQUILO C1-6, ENTRE OTROS; A4 ES H, CH3, ENTRE OTROS; A5 ES CICLOALQUILO C4-6, ALQUILO C1-6, ENTRE OTROS; R1 ES H, ALQUILO C1-3, CHF2, CF3, ENTRE OTROS; R2 ES H, F, CHF2, CF3, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: 5-(6-(((S)-1-CICLOPROPIL-2,2,2-TRIFLUOROETIL)AMINO)-4-(DIFLUOROMETIL)PIRIDIN-3-IL)-N-((1r,3S)-3-HIDROXICICLOBUTIL)-4-((S)-2-METILPIRROLIDIN-1-CARBONIL)TIAZOL-2-CARBOXAMIDA; 5-(6-(((S)-1-CICLOPROPIL-2,2,2-TRIFLUOROETIL)AMINO)-4-(DIFLUOROMETIL)PIRIDIN-3-IL)-N-((R)-3-HIDROXI-3-METILBUTAN-2-IL)-4-((S)-2-METILPIRROLIDIN-1-CARBONIL)TIAZOL-2-CARBOXAMIDA; ENTRE OTROS. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON MODULADORES DEL RECEPTOR NUCLEAR RORyt SIENDO UTILES PARA EL TRATAMIENTO DE ARTRITIS SORIASICA O SORIASIS
PE2018002176A 2016-04-27 2017-04-26 6-AMINOPIRIDIN-3-IL TIAZOLES COMO MODULADORES DE RORyT PE20190150A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662328074P 2016-04-27 2016-04-27

Publications (1)

Publication Number Publication Date
PE20190150A1 true PE20190150A1 (es) 2019-01-22

Family

ID=59215941

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2018002176A PE20190150A1 (es) 2016-04-27 2017-04-26 6-AMINOPIRIDIN-3-IL TIAZOLES COMO MODULADORES DE RORyT

Country Status (26)

Country Link
US (5) US10975068B2 (es)
EP (1) EP3448856B1 (es)
JP (1) JP6893218B2 (es)
KR (1) KR20180135962A (es)
CN (1) CN109415358B (es)
AR (1) AR108344A1 (es)
AU (1) AU2017255525A1 (es)
BR (1) BR112018071942A2 (es)
CA (1) CA3022318A1 (es)
CL (1) CL2018003044A1 (es)
CO (1) CO2018011633A2 (es)
CR (1) CR20180505A (es)
EA (1) EA036318B1 (es)
EC (1) ECSP18088146A (es)
ES (1) ES2906258T3 (es)
IL (1) IL262381A (es)
MA (1) MA44772A (es)
MX (1) MX2018013143A (es)
NI (1) NI201800109A (es)
PE (1) PE20190150A1 (es)
PH (1) PH12018502209A1 (es)
SG (1) SG11201809162XA (es)
SV (1) SV2018005772A (es)
TW (1) TW201803869A (es)
UY (1) UY37213A (es)
WO (1) WO2017189661A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201803869A (zh) * 2016-04-27 2018-02-01 健生藥品公司 作為ＲＯＲγＴ調節劑之６－胺基吡啶－３－基噻唑
CN112118841A (zh) 2018-03-12 2020-12-22 爱思凯利尔生物科学私人有限责任公司 螺环ROR-γ调节剂
EP3765009A4 (en) * 2018-03-12 2021-11-10 Escalier Biosciences, BV BICYCLIC ROR-GAMMA MODULATORS
ES2925473T3 (es) * 2018-06-18 2022-10-18 Janssen Pharmaceutica Nv Pirazoles de piridinilo como moduladores de RORyt
JP2021527660A (ja) 2018-06-18 2021-10-14 ヤンセン ファーマシューティカ エヌ．ベー． ＲＯＲγｔのモジュレータとしてのフェニル及びピリジニル置換イミダゾール
EP3790865A1 (en) 2018-06-18 2021-03-17 Janssen Pharmaceutica NV Phenyl substituted pyrazoles as modulators of roryt
ES2928246T3 (es) 2018-06-18 2022-11-16 Janssen Pharmaceutica Nv 6-aminopiridin-3-il pirazoles como moduladores de RORyt

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL91418A (en) 1988-09-01 1997-11-20 Rhone Poulenc Agrochimie (hetero) cyclic amide derivatives, process for their preparation and fungicidal compositions containing them
AU3201095A (en) 1994-07-27 1996-02-22 G.D. Searle & Co. Substituted thiazoles for the treatment of inflammation
NZ529043A (en) 2001-04-16 2006-11-30 Tanabe Seiyaku Co Large conductance calcium-activated K channel opener
US7138403B2 (en) 2001-08-13 2006-11-21 Janssen Pharmaceutica N.V. 2,4,5-trisubstituted thiazolyl derivatives and their antiinflammatory activity
DE60208815T2 (de) 2001-10-12 2006-07-20 Bayer Pharmaceuticals Corp., West Haven Phenyl substituierte 5-gliedrige stickstoff enthaltende heterocyclen zur behandlung von fettleibigkeit
RU2410377C2 (ru) 2005-02-16 2011-01-27 Солвей Фармасьютикалс Б.В. Производные 1н-имидазола как модуляторы рецептора каннабиноидов св2
WO2006124687A1 (en) 2005-05-12 2006-11-23 University Of Medicine And Dentistry Of New Jersey Opioid receptor subtype-selective agents
US8455658B2 (en) 2006-01-25 2013-06-04 Synta Pharmaceuticals Corp. Thiazole and thiadiazole compounds for inflammation and immune-related uses
WO2008064317A1 (en) 2006-11-22 2008-05-29 University Of Medicine And Dentistry Of New Jersey Lipophilic opioid receptor active compounds
WO2008064318A2 (en) 2006-11-22 2008-05-29 University Of Medicine And Dentistry Of New Jersey Peripheral opioid receptor active compounds
WO2009011850A2 (en) 2007-07-16 2009-01-22 Abbott Laboratories Novel therapeutic compounds
EP2591674B1 (de) 2008-07-17 2016-01-13 Bayer CropScience AG Heterocyclische Verbindungen als Schädlingsbekämpfungsmittel
TWI548411B (zh) 2009-04-28 2016-09-11 Kyowa Hakko Kirin Co Ltd Exercise disorder treatment
UA110097C2 (uk) 2009-09-02 2015-11-25 Терапевтичний агент для лікування розладів настрою
AU2010295481A1 (en) 2009-09-18 2012-03-08 Zalicus Pharmaceuticals Ltd. Aryl sulphone derivatives as calcium channel blockers
AR079022A1 (es) 2009-11-02 2011-12-21 Sanofi Aventis Derivados de acido carboxilico ciclico sustituidos con acilamino, su uso como productos farmaceuticos, composicion farmaceutica y metodo de preparacion
PT3002008T (pt) 2010-03-11 2018-12-24 Univ New York Compostos de amido como moduladores roryt e suas utilizações
WO2011112264A1 (en) 2010-03-11 2011-09-15 New York University Compounds as rorϒt modulators and uses thereof
WO2011115892A1 (en) 2010-03-15 2011-09-22 Griffin Patrick R Modulators of the retinoic acid receptor-related orphan receptors
WO2012027965A1 (en) 2010-09-01 2012-03-08 Glaxo Group Limited Novel compounds
US9505798B2 (en) 2010-11-29 2016-11-29 New York University Steroid compounds as RORyt modulators and uses thereof
EP2660597B1 (en) 2010-12-28 2017-09-13 ARKRAY, Inc. Method for determining condition of oral cavity and analytical tool, apparatus and program used for the method
WO2012129491A1 (en) 2011-03-24 2012-09-27 Abbott Laboratories Trpv3 modulators
WO2012158784A2 (en) 2011-05-16 2012-11-22 Theodore Mark Kamenecka Modulators of the nuclear hormone receptor ror
US9133128B2 (en) 2011-06-17 2015-09-15 Research Triangle Institute Pyrazole derivatives as cannabinoid receptor 1 antagonists
JP6054869B2 (ja) 2011-07-29 2016-12-27 武田薬品工業株式会社 複素環化合物
WO2013029338A1 (en) 2011-09-01 2013-03-07 Glaxo Group Limited Novel compounds
EP2753327A4 (en) 2011-09-09 2015-04-08 Univ New York AMIDOVER BINDINGS AS RORYT MODULATORS AND ITS USE
EP2800745B1 (en) 2011-12-02 2020-02-12 Phenex Pharmaceuticals AG Pyrrolo carboxamides as modulators of orphan nuclear receptor rar-related orphan receptor-gamma (rory, nr1f3) activity and for the treatment of chronic inflammatory and autoimmune diseases
US20130190356A1 (en) 2011-12-22 2013-07-25 Genentech, Inc. Benzyl sulfonamide derivatives as rorc modulators
BR112014029868A2 (pt) * 2012-05-31 2017-06-27 Phenex Pharmaceuticals Ag compostos, e, composição farmacêutica
JO3215B1 (ar) 2012-08-09 2018-03-08 Phenex Pharmaceuticals Ag حلقات غير متجانسة بها 5 ذرات تحتوي على النيتروجين بها استبدال بكربوكساميد أو سلفوناميد كمعدلات لمستقبل نووي غير محمي RORy
US9624210B2 (en) 2012-12-12 2017-04-18 Merck Sharp & Dohme Corp. Amino-pyrimidine-containing spleen tyrosine kinase (Syk) inhibitors
WO2013171729A2 (en) 2013-01-08 2013-11-21 Glenmark Pharmaceuticals S.A. Aryl and heteroaryl amide compounds as rorgamat modulator
CN105308037B (zh) 2013-06-04 2017-09-19 阿克图拉姆生命科学股份公司 三唑化合物及其作为γ分泌酶调节剂的用途
WO2015035278A1 (en) 2013-09-09 2015-03-12 Bristol-Myers Squibb Company RORγ MODULATORS
US20150072890A1 (en) 2013-09-11 2015-03-12 20/20 Gene Systems, Inc. Methods and compositions for aiding in the detection of lung cancer
EP3046906B1 (en) 2013-09-20 2017-08-16 Bristol-Myers Squibb Company Ror gamma modulators
EP3083561B1 (en) * 2013-10-15 2018-12-05 Janssen Pharmaceutica NV Heteroaryl linked quinolinyl modulators of roryt
US9403816B2 (en) 2013-10-15 2016-08-02 Janssen Pharmaceutica Nv Phenyl linked quinolinyl modulators of RORγt
US9624225B2 (en) 2013-10-15 2017-04-18 Janssen Pharmaceutica Nv Quinolinyl modulators of RORγt
RS58650B1 (sr) 2013-12-05 2019-05-31 Lead Pharma Holding Bv Ror gama (rory) modulatori
WO2015095795A1 (en) 2013-12-20 2015-06-25 Merck Sharp & Dohme Corp. TETRAHYDRONAPHTHYRIDINE, BENZOXAZINE, AZA-BENZOXAZINE, AND RELATED BICYCLIC COMPOUNDS FOR INHIBITION OF RORgamma ACTIVITY AND THE TREATMENT OF DISEASE
US9663502B2 (en) 2013-12-20 2017-05-30 Lycera Corporation 2-Acylamidomethyl and sulfonylamidomethyl benzoxazine carbamates for inhibition of RORgamma activity and the treatment of disease
CN106132931B (zh) 2014-01-06 2019-08-02 百时美施贵宝公司 碳环砜RORγ调节剂
EP3092221B1 (en) 2014-01-06 2018-10-17 Bristol-Myers Squibb Company Heterocyclic sulfones as ror-gamma modulators
ES2669208T3 (es) 2014-01-06 2018-05-24 Bristol-Myers Squibb Company Derivados de pirrolidinilsulfona y su uso como moduladores de ROR gamma
CN106061947B (zh) 2014-01-06 2019-12-03 百时美施贵宝公司 环己基砜RORγ调节剂
TWI659019B (zh) 2014-02-28 2019-05-11 日商帝人製藥股份有限公司 吡唑醯胺衍生物
WO2015139619A1 (zh) * 2014-03-18 2015-09-24 北京韩美药品有限公司 作为RORγ调节剂的化合物
US11084784B2 (en) 2014-03-27 2021-08-10 Piramal Enterprises Limited ROR-gamma modulators and uses thereof
CN103833672A (zh) 2014-03-28 2014-06-04 中国药科大学 一种n-丁基-5-苯基噻唑-4-甲酰胺类衍生物的制备方法
US10000488B2 (en) 2014-09-11 2018-06-19 Takeda Pharmaceutical Company Limited Heterocyclic compound
US9845319B2 (en) * 2014-10-30 2017-12-19 Janssen Pharmaceutiuca NV Amide substituted thiazoles as modulators of RORyt
CN107108598B (zh) 2014-10-30 2020-11-17 詹森药业有限公司 作为Rorγt调节剂的噻唑
JOP20200117A1 (ar) 2014-10-30 2017-06-16 Janssen Pharmaceutica Nv كحولات ثلاثي فلوروميثيل كمُعدلات للمستقبل النووي جاما تي المرتبط بحمض الريتيونَويك ROR?t
TW201803869A (zh) 2016-04-27 2018-02-01 健生藥品公司 作為ＲＯＲγＴ調節劑之６－胺基吡啶－３－基噻唑
AR108326A1 (es) 2016-04-27 2018-08-08 Samumed Llc Isoquinolin-3-il carboxamidas y preparación y uso de las mismas
AR108325A1 (es) 2016-04-27 2018-08-08 Samumed Llc Isoquinolin-3-il carboxamidas y preparación y uso de las mismas
TW201822637A (zh) 2016-11-07 2018-07-01 德商拜耳廠股份有限公司 用於控制動物害蟲的經取代磺醯胺類
JP2020059651A (ja) 2016-12-26 2020-04-16 科研製薬株式会社 ピラゾール誘導体及びそれを含有する医薬
FR3065000A1 (fr) 2017-04-06 2018-10-12 Galderma Research & Development Derives pyrazoles en tant qu'agonistes inverses du recepteur gamma orphelin associe aux retinoides ror gamma (t)
ES2928246T3 (es) 2018-06-18 2022-11-16 Janssen Pharmaceutica Nv 6-aminopiridin-3-il pirazoles como moduladores de RORyt
ES2925473T3 (es) 2018-06-18 2022-10-18 Janssen Pharmaceutica Nv Pirazoles de piridinilo como moduladores de RORyt
EP3790865A1 (en) 2018-06-18 2021-03-17 Janssen Pharmaceutica NV Phenyl substituted pyrazoles as modulators of roryt
JP2021527660A (ja) 2018-06-18 2021-10-14 ヤンセン ファーマシューティカ エヌ．ベー． ＲＯＲγｔのモジュレータとしてのフェニル及びピリジニル置換イミダゾール

Also Published As

Publication number Publication date
ECSP18088146A (es) 2018-11-30
US20210198251A1 (en) 2021-07-01
MX2018013143A (es) 2019-04-24
SG11201809162XA (en) 2018-11-29
US20230123208A1 (en) 2023-04-20
AU2017255525A1 (en) 2018-10-25
AR108344A1 (es) 2018-08-08
BR112018071942A2 (pt) 2019-02-05
US10975068B2 (en) 2021-04-13
SV2018005772A (es) 2019-03-28
JP6893218B2 (ja) 2021-06-23
PH12018502209A1 (en) 2019-10-28
MA44772A (fr) 2019-03-06
CN109415358B (zh) 2022-04-05
JP2019515924A (ja) 2019-06-13
WO2017189661A1 (en) 2017-11-02
CN109415358A (zh) 2019-03-01
UY37213A (es) 2017-10-31
ES2906258T3 (es) 2022-04-13
EP3448856A1 (en) 2019-03-06
EP3448856B1 (en) 2022-01-05
CA3022318A1 (en) 2017-11-02
CO2018011633A2 (es) 2018-11-13
CR20180505A (es) 2019-03-14
KR20180135962A (ko) 2018-12-21
NI201800109A (es) 2019-02-18
EA036318B1 (ru) 2020-10-26
EA201892438A1 (ru) 2019-04-30
US20210188836A1 (en) 2021-06-24
IL262381A (en) 2018-11-29
US20170313691A1 (en) 2017-11-02
TW201803869A (zh) 2018-02-01
CL2018003044A1 (es) 2019-02-01
US20210221804A1 (en) 2021-07-22

Similar Documents

Publication Publication Date Title
PE20190150A1 (es) 6-AMINOPIRIDIN-3-IL TIAZOLES COMO MODULADORES DE RORyT
CO2019007711A2 (es) N-[4-fluoro-5-[[(2s,4s)-2-metil-4-[(5-metil-1,2,4-oxadiazol-3-il)metoxi]-1-piperidil]metil]tiazol-2-il]acetamida como inhibidor de oga
PE20220253A1 (es) Benzamidas sustituidas con 1,3-tiazol-2-ilo
PE20181074A1 (es) Compuestos heteroaromaticos como inhibidores de btk
BR112017010354B8 (pt) Compostos de triazolopirimidina, seu uso, e composição farmacêutica
CL2017003127A1 (es) Derivados de 2,3-dihidro-4h-1,3-benzoxazin-4-ona como moduladores de receptor muscarinico m1 colinergico.
PE20190709A1 (es) Derivado de pirazolopiridinaque tiene el efecto agonista del receptor de glp-1
CL2016001911A1 (es) Compuesto heterocíclico fusionado
PE20160608A1 (es) Compuestos de quinolina selectivamente sustituida
MX385718B (es) Compuestos moduladores de fxr (nr1h4).
EA201791017A1 (ru) Гидроксисодержащие соединения, модулирующие fxr (nr1h4)
NZ732210A (en) Novel fxr (nr1h4) modulating compounds
DOP2016000242A (es) Uso de compuestos heterocíclicos para controlar nematodos
PE20161572A1 (es) Compuestos como moduladores de ror gamma
UY36619A (es) Amidas cíclicas sustituidas como herbicidas
PE20180024A1 (es) Triazolopirazinonas como inhibidores de pde1
UY31863A (es) Combinaciones de drogas que comprenden un inhibidor de dgat y un agonista de ppar
PE20180355A1 (es) Desacetoxitubulisina h y analogos de esta
ECSP18010535A (es) 2-amino-3-fluoro-3-(fluorometil)-6-meti-6-fenil-3,4,5,6-tetrahidropiridinas como inhibidores de bace1
MX2018012085A (es) Compuestos agonistas de gpr119 y metodo para tratar enfermedades y afecciones mediado a traves de gpr119.
BR112016024936A2 (pt) moduladores de gpr40 à base de pirrolidina para tratamento de doenças como diabetes
UY37517A (es) Métodos de síntesis de compuestos tiazoles sustituidos
BR112017008852A2 (pt) tiazóis substituídos com amida como moduladores do roryt
CL2018002089A1 (es) Maleato de agonista de tlr7, sus formas cristalinas c, d y e, sus procesos de preparación y su uso
MX2019003818A (es) Metodo para la sintesis de derivado de 3-fenil-2,3,4,8,9,10-hexahi dropiran [2,3-f] cromeno e isomero optico del mismo.